<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04505163</url>
  </required_header>
  <id_info>
    <org_study_id>PIVoTAL-IDE</org_study_id>
    <nct_id>NCT04505163</nct_id>
  </id_info>
  <brief_title>Left Atrial Posterior Wall and PV Isolation Using Cryoballoon for Treatment of Persistent AF</brief_title>
  <acronym>PIVoTAL-IDE</acronym>
  <official_title>Left Atrial Posterior Wall Isolation in Conjunction With Pulmonary Vein Isolation Using the Cryoballoon for Treatment of Persistent Atrial Fibrillation (PIVoTAL) - IDE Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dignity Health Medical Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mercy General Hospital and Dignity Health Medical Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Thomas Heart</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UC Health Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Staten Island University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MedStar Georgetown University Hospital and Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tampa Cardiac Specialists</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bethesda North Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio Health Physician Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heart Center, Japan Red Cross Yokohama City Bay Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Texas Cardiac Arrhythmia Institute At St. Davids Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Luke's Hospital and Health Network, Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dignity Health Medical Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study it to learn whether pulmonary vein isolation (PVI) along with&#xD;
      isolation of the posterior left atrial wall (PWI) in the region of the pulmonary venous&#xD;
      component will reduce the likelihood of atrial fibrillation (AF) recurrence in patients with&#xD;
      persistent atrial fibrillation at 12 months, after a single ablation procedure, in comparison&#xD;
      to PVI alone.&#xD;
&#xD;
      The investigator hypothesizes that the combination of PVI + PWI will result in a significant&#xD;
      reduction in recurrence of atrial fibrillation at 12 months after ablation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with persistent atrial fibrillation will be enrolled in this multi-center,&#xD;
      randomized, prospective, single-blinded study. After catheter ablation (isolation) of the&#xD;
      pulmonary veins (PVI) and while still in the cardiac electrophysiology laboratory, all&#xD;
      patients will be randomized to either PVI alone or the combination of PVI + posterior left&#xD;
      atrial wall isolation (PWI). For patients randomized to PVI, their ablation procedure will be&#xD;
      completed at that time. For those patients randomized to PVI + PWI, they will have additional&#xD;
      ablation to achieve PWI.&#xD;
&#xD;
      All study patients will have the same follow-up after their ablation procedure, including&#xD;
      clinic visits at 3, 6, and 12 months and a heart event monitor for 7-14 days before these&#xD;
      visits. An echocardiogram (heart ultrasound) is performed at 6 to 12 months after the&#xD;
      ablation. Blood thinners are recommended for two months after ablation and then the need for&#xD;
      continued use of blood thinners will be based on individual patient's medical history, stroke&#xD;
      risk and the decision of the study doctor. Information about the patients' medical history,&#xD;
      heart arrhythmias and atrial fibrillation will be collected during the study which will be&#xD;
      analyzed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12-month freedom from recurrent atrial fibrillation</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants with recurrent atrial fibrillation following catheter ablation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All atrial arrhythmia recurrences</measure>
    <time_frame>During a follow-up period of 12 months</time_frame>
    <description>Number of atrial arrhythmia recurrences after the 90-day blanking period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Canadian Cardiovascular Society Severity of Atrial Fibrillation Scale (CCS-SAF)</measure>
    <time_frame>During a follow-up period of 12 months</time_frame>
    <description>Change in CCS-SAF from baseline to 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Atrial Fibrillation Effect on Quality of Life Questionnaire (AFEQT)</measure>
    <time_frame>During a follow-up period of 12 months</time_frame>
    <description>Change in AFEQT from baseline to 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple procedure success</measure>
    <time_frame>During a follow-up period of 12 months</time_frame>
    <description>Absence of recurrent atrial arrhythmias after one or more ablation procedure(s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative reduction in atrial fibrillation burden</measure>
    <time_frame>During a follow-up period of 12 months</time_frame>
    <description>Reduction in the burden of atrial fibrillation (in percentage) following catheter ablation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from cardioversion for recurrent atrial arrhythmias</measure>
    <time_frame>During a follow-up period of 12 months</time_frame>
    <description>Electrical or pharmacological cardioversion for treatment of recurrent atrial arrhythmias not required</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from repeat atrial fibrillation ablation</measure>
    <time_frame>During a follow-up period of 12 months</time_frame>
    <description>Repeat ablation for atrial fibrillation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Atrial Diameter (Size) as predictor of atrial fibrillation recurrence</measure>
    <time_frame>During a follow-up period of 12 months</time_frame>
    <description>Change in left atrial diameter (in millimeters) following ablation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction as predictor of atrial fibrillation recurrence</measure>
    <time_frame>During a follow-up period of 12 months</time_frame>
    <description>Change in left atrial ejection fraction (in percentage) following ablation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association Functional Class as predictor of atrial fibrillation recurrence</measure>
    <time_frame>During a follow-up period of 12 months</time_frame>
    <description>Change in New York Heart Association Functional Class following ablation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">366</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Standard Cryoballoon Pulmonary Vein Isolation (PVI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard cryoballoon pulmonary vein isolation alone using the Arctic Front Advance Cryoablation System family of cardiac ablation catheters</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cryoballoon PVI + Posterior Wall Isolation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cryoballoon pulmonary vein isolation in conjunction with posterior wall isolation using the Arctic Front Advance Cryoablation System family of cardiac ablation catheters</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard Cryoballoon Pulmonary Vein Isolation (PVI)</intervention_name>
    <description>Arctic Front Advance cryoballoon ablation system to ablate the pulmonary veins to achieve PVI alone</description>
    <arm_group_label>Standard Cryoballoon Pulmonary Vein Isolation (PVI)</arm_group_label>
    <other_name>Arctic Front Advance Cardiac Cryoablation System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cryoballoon PVI + Posterior Wall Isolation</intervention_name>
    <description>Arctic Front Advance Cardiac Cryoballoon Ablation System to ablate the pulmonary veins and the left atrial posterior wall to achieve PVI + posterior wall isolation within the region of the pulmonary venous component</description>
    <arm_group_label>Cryoballoon PVI + Posterior Wall Isolation</arm_group_label>
    <other_name>Arctic Front Advance Cardiac Cryoablation System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consistent with the current definitions, all patients with Persistent AF must exhibit&#xD;
             an episode of continuous AF that is sustained &gt;7 days.&#xD;
&#xD;
          -  Patients must have symptomatic Persistent AF refractory or intolerant to at least one&#xD;
             class I or class III antiarrhythmic drug&#xD;
&#xD;
          -  Males and females with an age &gt;18 years undergoing a first-time catheter ablation of&#xD;
             AF; prior ablation of a right atrial cardiac arrhythmia (i.e., typical right atrial&#xD;
             flutter) is permitted&#xD;
&#xD;
          -  All patients must understand the requirements of the study and be willing to comply&#xD;
             with the post-study follow-up requirements&#xD;
&#xD;
          -  Patients must have documented episode of AF greater than 7 days in the year prior to&#xD;
             the procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any reversible cause of AF (post-operative, thyroid disorder, etc.)&#xD;
&#xD;
          -  Patients with cerebral ischemic events (stroke or transient ischemic attack),&#xD;
             myocardial infarction or unstable angina in the previous 2 months&#xD;
&#xD;
          -  Patients with any corrected or uncorrected congenital heart disease&#xD;
&#xD;
          -  Patients with a history of hypertrophic cardiomyopathy&#xD;
&#xD;
          -  Patients with cardiomyopathy and a left ventricular ejection fraction &lt;40%&#xD;
&#xD;
          -  Congestive heart failure, class IV&#xD;
&#xD;
          -  Left atrial (LA) diameter &gt;48 mm (parasternal long axis view)&#xD;
&#xD;
          -  Patients with left atrial thrombus&#xD;
&#xD;
          -  Women who are known to be pregnant or have had a positive Î²-HCG (human chorionic&#xD;
             gonadotropin) test 7 days prior to procedure&#xD;
&#xD;
          -  Patients whose life expectancy is &lt;1 year&#xD;
&#xD;
          -  History of left-sided left atrial ablation (catheter or surgically-based)&#xD;
&#xD;
          -  Mental impairment precluding the patient from providing informed consent or completing&#xD;
             appropriate follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arash Aryana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mercy General Hospital and Dignity Health Medical Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arash Aryana, MD</last_name>
    <phone>916-453-2684</phone>
    <email>arash.aryana@dignityhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shelley Allen, RN</last_name>
    <phone>916-453-2626</phone>
    <email>shelley.allen@dignityhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mercy General Hospital and Dignity Health Medical Foundation</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arash Aryana, MD</last_name>
      <phone>916-453-2684</phone>
      <email>arash.aryana@dignityhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Shelley Allen, RN</last_name>
      <phone>9164532626</phone>
      <email>shelley.allen@dignityhealth.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sanjiv Narayan, MD</last_name>
      <email>sanjiv1@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCHealth Medical Center</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ethan Ellis, MD</last_name>
      <email>ethan.ellis@uchealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MedStar Georgetown University Hospital and Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sung Lee, MD</last_name>
      <email>Sung.W.Lee@medstar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tampa Cardiac Specialists</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33558</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kevin Makati, MD</last_name>
      <email>kmakati@tampacardiac.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Tadros, MD</last_name>
      <email>thtadros@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andre d'Avila, MD</last_name>
      <email>andredavila@me.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Staten Island University Hospital</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcin Kowalski, MD</last_name>
      <email>marcin212@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bethesda North Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dilesh Patel, MD</last_name>
      <phone>248-961-4863</phone>
      <email>dilesh_patel@trihealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio Health Physician Group</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anish K Amin, MD</last_name>
      <phone>614-262-6772</phone>
      <email>anishamin@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jaret Tyler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's University Health Network</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven M Stevens, MD</last_name>
      <phone>484-526-7843</phone>
      <email>steven.stevens@sluhn.org</email>
    </contact>
    <investigator>
      <last_name>Sudip Nanda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Thomas Heart</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James H Baker, MD</last_name>
      <email>jbaker525@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Martin A Espinosa-Ginic, MD</last_name>
      <email>martin.espinosaginic@STH.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia Institute &amp; St. David's Medical Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Natale, MD</last_name>
      <email>Andrea.Natale@stdavids.com</email>
    </contact>
    <contact_backup>
      <last_name>Amin Al-Ahmad, MD</last_name>
      <email>Amin.AlAhmad@stdavids.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Heart Center, Japan Red Cross Yokohama City Bay Hospital</name>
      <address>
        <city>Yokohama City</city>
        <state>Naka-ward</state>
        <zip>231-8682</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kaoru Okishige, MD</last_name>
      <email>okishige@yo.rim.or.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 10, 2020</study_first_submitted>
  <study_first_submitted_qc>August 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2020</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Catheter ablation</keyword>
  <keyword>Cryoablation</keyword>
  <keyword>Cryoballoon</keyword>
  <keyword>Posterior left atrial wall ablation</keyword>
  <keyword>Pulmonary vein isolation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

